Navigation Links
Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
Date:9/6/2011

LAKE FOREST, Ill., Sept. 6, 2011 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, today announced positive results from a Phase I U.S. clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia. Hospira's trial met its key endpoint, showing equal pharmacokinetics, or blood level and distribution in the body, for Hospira's EPO and the reference product, Amgen's Epogen®. Erythropoietin is a treatment for anemia associated with chronic renal failure and chemotherapy.

The controlled, randomized trial of 100 patients on hemodialysis who had already been treated with Epogen took place at 20 different hemodialysis centers across the United States. Patients in the trial were treated with both Epogen and Hospira's EPO, with each patient receiving one drug first and then being switched to the second drug, spending one week on each. Besides showing equivalent pharmacokinetics, the trial showed no difference in patient safety between the two drugs, a secondary endpoint. The positive Phase I results pave the way for Hospira's planned Phase III U.S. program comparing safety and efficacy of the two products.

"The successful completion of our Phase I EPO trial is an important step for Hospira's U.S. biosimilars program," said Sumant Ramachandra, M.D., Ph.D., senior vice president, Research & Development and Medical & Regulatory Affairs, and chief scientific officer, Hospira. "We look forward to starting our Phase III U.S. program, and are committed to building on our success with biosimilars in Europe and Australia by making affordable, safe and effective biosimilars available to U.S. patients and their healthcare providers once patents expire over the next several years."

The first Phase III U.S. trial, scheduled to
'/>"/>

SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Hospira to Host 2011 Investor Day
2. Hospira to Present at the Morgan Stanley Global Healthcare Conference
3. Hospira Expands Board of Directors
4. Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection
5. Hospira Reports Second-Quarter 2011 Results
6. Hospira to Host Conference Call for Second-Quarter 2011 Results
7. Hospira Receives Health Canada Regulatory Approval for Symbiq™ Infusion System Software Upgrade
8. Hospira to Present at the Sanford C. Bernstein Twenty-Seventh Annual Strategic Decisions Conference 2011
9. Hospira Highlights Progress in 2010 at Its 2011 Annual Meeting of Shareholders
10. Hospira Reports First-Quarter 2011 Results
11. Hospira Board Authorizes $1 Billion Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015  Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today it has completed enrollment of ... Review Committee (DRC) earlier this year, into the ... a first-in-class innate defense regulator (IDR) and is ...
(Date:8/31/2015)... Aug. 31, 2015  QT Vascular Ltd., together with its ... with its subsidiaries, the "Group"), a global company ... advanced therapeutic solutions for the minimally invasive treatment ... of the below-the-knee ("BTK") cohort of patients in ... presented on August 15, 2015 at the 5th ...
(Date:8/30/2015)... y LONDRES, August 30, 2015 ... holística de l cuidado al paciente ... trayecto   Royal Philips  ... europeo de IntelliSpace Cardiovascular , un sistema web ... herramientas para acceder, analizar y compartir imágenes cardiovasculares e ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3
... Caliper Life Sciences, Inc. (Nasdaq: ... and services for drug discovery and life sciences ... Austria AG for the co-development and manufacture of ... The agreement combines Sony DADC,s premier Blu-ray Disc™ ...
... Nov. 3, 2010 Cyberonics, Inc. (Nasdaq: CYBX ) ... second quarter ended October 29, 2010 of its fiscal year ending ... ET.  The company will conduct a conference call to discuss those ... Fiscal Year 2011 Second Quarter Results Conference Call InstructionsTo ...
Cached Medicine Technology:Caliper Life Sciences and Sony DADC Collaborate to Develop Plastic Microfluidic Solutions 2Cyberonics Announces Conference Call to Discuss Fiscal Year 2011 Second Quarter Financial Results 2
(Date:9/1/2015)... ... September 01, 2015 , ... September is Baby Safety ... use safety labels and stickers to keep little ones' safety top of mind at ... Month has a particular focus. According to the JPMA's Baby Safety Zone website, this ...
(Date:8/31/2015)... ... September 01, 2015 , ... The PT Outcomes Registry is an ... for physical therapy patients. The Registry is being developed by the American Physical Therapy ... are happy to be selected to contribute FOTO Outcomes measures as one of the ...
(Date:8/31/2015)... ... August 31, 2015 , ... ITC Global Translations website, ... for specific translation services within the medical and pharmaceutical industries. These are industries ... successful work. , ITC Global Translations specializes in professional translation services for materials ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... their new “ InstantQuote ” tool, which summarizes all available plans, plan maximums, ... technology tool is designed to help India Network members make an informed decision ...
(Date:8/31/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... by Movestrong, has launched pre and postnatal fitness classes. , Starting ... Thursdays. The classes are called "The Mom Bod" and "Healthy Body, Healthy Baby." ...
Breaking Medicine News(10 mins):Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 2Health News:Lightning Labels Can Help Make A Difference This Baby Safety Month 3Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2
... -- Revenue of $99.7 million, up 23.6% year-over-year ... -- Net income of $11.3 million or $0.32 per diluted share, ... 2007Full Year 2008 Highlights: -- Revenue of $423.4 ... basis -- Net income of $24.0 million or ...
... (NASDAQ: QLTI ; TSX: QLT) announced that the ... "Court of Appeals") today denied its Petition for Panel Rehearing ... 2009 Court of Appeals decision. The QLT Petition was filed ... Appeals decision upheld the liability and damages aspect of the ...
... Therapeutics, LLC, a biopharmaceutical company focused on the ... the appointment of Dr. Marcel Rozencweig as Senior ... joining Sopherion, Dr. Rozencweig was a key Clinical ... of the Sopherion Protocol Development Team for Myocet."I ...
... Hard-Pressed Business SectorKIRKLAND, Wash., Feb. 24 For people ... healthcare front. They can often insure themselves for less, ... can use company dollars for a tax-deductible plan for ... of the Board of LTC Financial Partners LLC (LTCFP), ...
... Hazardous Drug ExposureCOLUMBUS, Ohio, Feb. 24 In ... of hazardous drugs in the healthcare setting, April 2009 ... Month with Monday, April 20, 2009 being declared the ... of National Safe Handling Awareness Month follows the need ...
... translation and localization services focused on quality and clarity for a ... a new program of adding global business reference material to its website ... , ... Chicago, IL (Vocus) February 24, 2009 -- Businesses of all sizes ...
Cached Medicine News:Health News:Symmetry Medical Reports Fourth Quarter and Full Year 2008 Financial Results 2Health News:Symmetry Medical Reports Fourth Quarter and Full Year 2008 Financial Results 3Health News:Symmetry Medical Reports Fourth Quarter and Full Year 2008 Financial Results 4Health News:Symmetry Medical Reports Fourth Quarter and Full Year 2008 Financial Results 5Health News:Symmetry Medical Reports Fourth Quarter and Full Year 2008 Financial Results 6Health News:Symmetry Medical Reports Fourth Quarter and Full Year 2008 Financial Results 7Health News:Symmetry Medical Reports Fourth Quarter and Full Year 2008 Financial Results 8Health News:QLT petition for rehearing of Massachusetts Eye and Ear Infirmary litigation is denied 2Health News:QLT petition for rehearing of Massachusetts Eye and Ear Infirmary litigation is denied 3Health News:Sopherion Therapeutics Announces Appointment of New Senior Executive Vice President for Clinical Affairs 2Health News:Long Term Care Insurance for Business Owners & Executives: Tax Benefits Often Overlooked 2Health News:April 2009 Declared National Safe Handling Awareness Month 2Health News:April 2009 Declared National Safe Handling Awareness Month 3Health News:April 2009 Declared National Safe Handling Awareness Month 4Health News:Argo Translation Adds New Resources for Conducting Global Business to ArgoTrans.com 2
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
This instrument can be used as a spoon forceps in gynecologic surgery....
This is a single-action instrument that features a spring handle....
Medicine Products: